| Literature DB >> 30002275 |
Jinglu Zhang1, Run Han2, Weijie Chen3, Weixiang Zhang4, Ying Li5, Yuanhui Ji6, Lijiang Chen7, Hao Pan8, Xinggang Yang9, Weisan Pan10, Defang Ouyang11.
Abstract
Background: Solid dispersions are an effective formulation technique to improve the solubility, dissolution rate, and bioavailability of water-insoluble drugs for oral delivery. In the last 15 years, increased attention was focused on this technology. There were 23 marketed drugs prepared by solid dispersion techniques. Objective: This study aimed to report the big picture of solid dispersion research from 1980 to 2015. Method: Scientific knowledge mapping tools were used for the qualitative and the quantitative analysis of patents and literature from the time and space dimensions.Entities:
Keywords: CiteSpace; big data; literature; patent; scientific knowledge mapping; solid dispersion
Mesh:
Substances:
Year: 2018 PMID: 30002275 PMCID: PMC6099565 DOI: 10.3390/molecules23071697
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Categorization of solid dispersion publications by documents types from1980 to 2015.
Figure 2The publication number (red column) and cumulative percentage (blue curve) from 1980 to 2015.
Global publication shares of the top 10 most productive countries.
| Rank | Countries/Territories | TP (%) | TC | ACP |
|---|---|---|---|---|
| 1 | USA | 633(18.34) | 15,096 | 23.85 |
| 2 | Japan | 383(11.10) | 6506 | 16.99 |
| 3 | China | 370(10.72) | 3890 | 10.51 |
| 4 | India | 349(10.11) | 3219 | 9.22 |
| 5 | England | 289(8.37) | 5495 | 19.01 |
| 6 | South Korea | 212(6.14) | 2728 | 12.87 |
| 7 | Germany | 151(4.38) | 3770 | 24.97 |
| 8 | Belgium | 146(4.23) | 3929 | 26.91 |
| 9 | Egypt | 124(3.59) | 808 | 6.52 |
| 10 | Italy | 118(3.42) | 2359 | 19.99 |
Note: TP: total number of publications, TC: total citation times, APC: average citation times per paper.
Figure 3Annual publication numbers of top five productive countries.
Figure 4Global geographic distributions of authors according to the total number of publications by country: (a) North America and Europe; (b) Asia. Each yellow node showed individual researches and one red link between two nodes represented the collaboration at one publication.
Figure 5Country collaboration relationships network. Different colors in the figure represent different time slices, deep blue: 1980 to1985, sky blue: 1986 to 1991, pink green: 1992 to 1997, green: 1998 to 2003, yellow: 2004 to 2009 and orange: 2010 to 2015. The diameter of each circle represents the publication number of the country. The thickness of the connect line represents the intensity of country cooperation.
Productivity and impact of top 20 the most active institutions.
| Ranking | Institutes | Country | Records | Average Citation |
|---|---|---|---|---|
| 1 | Purdue University | USA | 107 | 26.79 |
| 2 | Catholic University of Louvain | Belgium | 92 | 34.67 |
| 3 | Shenyang Pharmaceutical University | China | 73 | 12.96 |
| 4 | Yeungnam University | South Korea | 58 | 12.98 |
| 5 | University of Texas Austin | USA | 55 | 32.54 |
| 6 | University of London | UK | 46 | 17.44 |
| 7 | Johnson & Johnson | USA | 45 | 37.42 |
| 8 | Chiba University | Japan | 42 | 12.55 |
| 9 | University of Copenhagen | Denmark | 42 | 14.83 |
| 10 | Roche Holding | Swiss | 41 | 18.51 |
| 11 | Novartis | Swiss | 38 | 23.08 |
| 12 | Aristotle University of Thessaloniki | Greece | 37 | 30.27 |
| 13 | Chungnam National University | South Korea | 37 | 23.38 |
| 14 | Meijo University | Japan | 36 | 18.25 |
| 15 | University of Greenwich | UK | 36 | 11.06 |
| 16 | Hanyang University | South Korea | 35 | 8.31 |
| 17 | AstraZeneca | UK | 34 | 21.12 |
| 18 | King Saud University | Saudi Arabia | 32 | 5.81 |
| 19 | Tabriz University MED SCI | Azerbaijan | 31 | 18.94 |
| 20 | Bristol Myers SQUIBB Co. | USA | 30 | 25.50 |
Top 20 global patentees.
| Ranking | Assignee Name | Assignee Code | Records |
|---|---|---|---|
| 1 | Abbott GmbH & Co. KG | ABBO-C | 46 |
| 2 | Reddys Lab Ltd. | REDY-C | 20 |
| 3 | Vertex Pharmaceuticals | VERT-C | 17 |
| 4 | Hetero Research Foundation | HETE-N | 16 |
| 5 | Hanmi Pharmaceutical Co., Ltd. | HANM-C | 15 |
| 6 | Dow Global Technologies LLC | DOWC-C | 14 |
| 7 | Pfizer Inc. | PFIZ-C | 13 |
| 8 | AbbVie Deutschland GmbH & Co. KG | ABBV-N | 12 |
| 9 | AstraZeneca UK | ASTR-C | 12 |
| 10 | Novartis International AG | NOVS-C | 12 |
| 11 | Cadila Healthcare | CDLA-C | 11 |
| 12 | Sandoz AG | SANO-C | 11 |
| 13 | Shenyang Pharmaceutical University | UYSH-N | 10 |
| 14 | Ranbaxy Laboratories Limited | RANB-C | 10 |
| 15 | Sun Yat-Sen University | UYSY-C | 10 |
| 16 | Bend Research | BEND-N | 9 |
| 17 | China Pharmaceutical University | UYCP-C | 9 |
| 18 | Xinjiang Medical University | UYXI-N | 8 |
| 19 | Astellas Pharma US, Inc. | ASTE-C | 8 |
| 20 | Takeda Pharmaceutical Company Limited | TAKE-C | 8 |
Figure 6Mapping of Institution cooperation network. Different colors represent different time slices, deep blue: 1980 to1985, sky blue: 1986 to 1991, pink green: 1992 to 1997, green: 1998 to 2003, yellow: 2004 to 2009 and orange: 2010 to 2015 from 1980 to 2015. The diameter of each circle represents the publication number of the institution. The thickness of the connect line represents the intensity of institution cooperation.
Figure 7Mapping of authors’ cooperation network. The size of node represents the author’s publication number and the link strength between two nodes means the collaboration intensity between authors.
Top 10 active journal and publication number about solid dispersions from 1980 to 2015.
| Order | Source Titles | Publication Number |
|---|---|---|
| 1 |
| 519 |
| 2 |
| 303 |
| 3 |
| 240 |
| 4 |
| 125 |
| 5 |
| 121 |
| 6 |
| 119 |
| 7 |
| 107 |
| 8 |
| 105 |
| 9 |
| 93 |
| 10 |
| 91 |
Figure 8Map of the journal co-citation network. Different colors represent different time slices, deep blue:1980 to1985, sky blue: 1986 to 1991, pink green: 1992 to 1997, green: 1998 to 2003, yellow: 2004 to 2009 and orange: 2010 to 2015. Each circle represents for one journal. The size of circles was proportional to the citation number. The purple ring of the circles indicates the core journals.
Keywords burst with time. The time interval was depicted as a blue line, and red line meant the key word burst emergence in this period.
| Keywords | Strength | Begin | End | 1991–2015 |
|---|---|---|---|---|
| polyethylene glycol | 22.4985 | 1991 | 2007 |
|
| nifedipine | 17.5424 | 1991 | 2006 |
|
| eudragit | 3.6793 | 1991 | 2006 |
|
| hydroflumethiazide | 4.7328 | 1991 | 2005 |
|
| coprecipitate | 7.7031 | 1991 | 2004 |
|
| differential scanning calorimetry | 4.7786 | 1991 | 2004 |
|
| X-ray powder diffraction | 4.5573 | 1991 | 2004 |
|
| phosphatidylcholine | 8.2027 | 1991 | 2001 |
|
| enteric coating agent | 7.4571 | 1991 | 2001 |
|
| griseofulvin | 9.8475 | 1991 | 1996 |
|
| sodium dodecyl sulfate | 4.486 | 1991 | 1996 |
|
| coevaporate | 4.8627 | 1992 | 2008 |
|
| ethyl cellulose | 3.7864 | 1993 | 2009 |
|
| tolbutamide | 5.6716 | 1993 | 2006 |
|
| triamterene | 7.1155 | 1993 | 2004 |
|
| hydroxypropyl cellulose | 5.7617 | 1993 | 2001 |
|
| oxazepam | 3.6394 | 1993 | 1998 |
|
| ethenzamide | 4.8554 | 1994 | 2006 |
|
| poly(ethylene oxide) | 3.5901 | 1995 | 2007 |
|
| albendazole | 3.5638 | 1995 | 2003 |
|
| Naproxen | 4.4423 | 1996 | 2006 |
|
| temazepam | 6.899 | 1998 | 2008 |
|
| diflunisal | 4.2489 | 1998 | 2002 |
|
| ketoprofen | 5.0229 | 1999 | 2007 |
|
| controlled release | 4.4497 | 1999 | 2002 |
|
| gelucire 44/14 | 4.2429 | 2000 | 2003 |
|
| carbamazepine | 3.3727 | 2000 | 2002 |
|
| crospovidone | 4.1851 | 2002 | 2007 |
|
| supercritical carbon dioxide | 6.2183 | 2003 | 2009 |
|
| polyvinylpyrrolidone | 7.6429 | 2004 | 2009 |
|
| eutectic mixture | 4.0659 | 2004 | 2009 |
|
| rofecoxib | 5.144 | 2004 | 2007 |
|
| melt agglomeration | 4.9545 | 2005 | 2010 |
|
| microsphere | 7.1443 | 2006 | 2009 |
|
| chitosan | 4.3876 | 2006 | 2009 |
|
| itraconazole | 4.9696 | 2007 | 2008 |
|
| granulation | 4.2664 | 2007 | 2008 |
|
| ibuprofen | 4.8525 | 2008 | 2009 |
|
| piroxicam | 4.126 | 2009 | 2010 |
|
| beta cyclodextrin | 4.2647 | 2010 | 2011 |
|
| curcumin | 4.7142 | 2013 | 2015 |
|
Terms of active research clusters with time from co-citation analysis.
| Categories | Year | |||
|---|---|---|---|---|
| ~1980 | 1980~1996 | 1997~2003 | 2004~2010 | |
| Model drug | Diflunisal, diazepam | sulfathiazole, paracetamol, zolpidem, glucosamine | sibutramine, tranilast, megestrol acetate | felodipine, kinetisola, itraconazole, ketoprofen, glibenclamide |
| Carrier | polyethlene glycol 6000, amphiphilicity | sodium lauryl sulfate, hydroxypropyl methylcellulose, eudragit, cellulose derivative matrice, lactose, polyethlene glycol, povidone-sodium, cholate-phospholipid mixed micelle | N/A | Polyvinylpyrrolidone |
| Preparation method | N/A | spray | supercritical fluid | fusion production, |
| Characterizations | N/A | N/A | N/A | thermoanalytical measurement, |
| Mechanism | N/A | amorphous drug stabilization, sustained-release, thermal behavior, dissolution behaviour | crystalline property, solid nano dispersion system | binary dispersion, quantifying drug crystallinity, in vivo drug absorption, drug-release properties, ab initio polymer selection, physical stability studies, acidic decomposition characteristic, free amorphous solid dispersion, glassy form, drug-carrier interaction, heterogeneity, excipient distribution, phase diagram, enthalpy relaxation studies, crystal engineering principle, moisture, miscibility |
Examples of commercially available solid dispersion products.
| Order | Products | API | Excipient | Manufacturing Method | Dosage Form | Company |
|---|---|---|---|---|---|---|
| 1 | Afeditab | Nifedipine | Poloxamer/PVP | Spray drying | Tablet | Elan |
| 2 | Afinitor | Everolimus | Hydroxypropyl methylcellulose | Spray dried | Tablet | Novartis |
| 3 | Certican | Everolimus | Hydroxypropyl methylcellulose | Spray dried | Tablet | Novartis |
| 4 | Cesamet | Nabilone | PVP | - | Tablet | Valeant |
| 5 | Crestor | Rosuvastatin | HPMC | Spray drying | Tablet | AstraZeneca |
| 6 | Florfenicol | Florfenicol | Enteric cellulose | - | Powder | Hebei Huaqiang |
| 7 | Gris-PEG | Griseofulvin | PEG-6000 | Melt-extrusion | Tablet | Pedinol |
| 8 | Incivek | Teleprevir | HPMCAS-M | Spray drying | Tablet | Vertex |
| 9 | Intelence | Etravirin | HPMC | Certican | Tablet | Tibotec |
| 10 | Isoptin | Verapamil | HPC/HPMC | Spray drying | Tablet | Abbvie |
| 11 | Kaletra | Lopinavir | PVP | Melt extrusion | Capsule | Abbvie |
| 12 | Kalydeco | Ivacaftor | HPMCAS | Spray drying | Tablet | Vertex |
| 13 | Nivadil | Nivaldipine | HPMC | Spray drying | Tablet | Fujisawa |
| 14 | Novir | Ritonavir | PVP | Melt-extrusion | Tablet | Abbott |
| 15 | Onmel | Itraconazole | HPMC | Melt-extrusion | Tablet | Sebela |
| 16 | Prograf | Tacrolimus | HPMC | Spray drying | Capsule | Fujisawa |
| 17 | Rezulin | Troglitazone | HPMC | Spray drying | Tablet | Parke Davis |
| 18 | Shuilinjia | Silibinin | Lecithin | - | Capsules | Tianjin Tasly |
| 19 | Sporanox | Itraconazole | HPMC | Spray drying on sugar beads | Capsule | Janssen |
| 20 | Stivarga | Regorafenib | Povidone K25 | - | Tablet | Bayer |
| 21 | Votubia | Everolimus | Hydroxypropyl methylcellulose | Spray dried | Tablet | Novartis |
| 22 | Zelboraf | Vemurafenib | Hypromellose acetate succinate | Precipitation | Tablet | Roche |
| 23 | Zortess | Everolimus | HPMC | Spray drying | Tablet | Novartis |